Table 1.

Inhibitory effects (%) ^a of compounds 10–22 on K562 cell viability (mean ± SD; n = 4).

Comp.	1 µM	50 µM	100 µM
10	44.16 ± 3.59	41.71 ± 1.01	26.71 ± 3.91
11	49.69 ± 0.68	45.85 ± 3.07	36.18 ± 1.00
12	31.42 ± 1.18	38.38 ± 3.04	38.54 ± 4.24
13	32.87 ± 3.20	23.93 ± 3.04	31.64 ± 2.93
14	37.71 ± 2.20	49.33 ± 4.70	56.82 ± 1.36
15	40.59 ± 2.47	44.32 ± 1.08	43.64 ± 3.85
16	20.33 ± 1.13	65.61 ± 2.42	77.73 ± 2.01
17	26.77 ± 0.99	56.10 ± 3.58	63.70 ± 0.21
18	37.88 ± 3.86	69.63 ± 0.92	80.05 ± 0.28
19	12.48 ± 3.57	54.56 ± 2.97	71.76 ± 3.73
20	39.87 ± 4.43	43.86 ± 1.92	49.38 ± 2.50
21	20.64 ± 1.91	18.60 ± 2.65	21.84 ± 3.39
22	46.11 ± 4.1	45.9 ± 3.39	37.61 ± 0.38

^a inhibition (%) after 48 h of continuous treatment (n = 4), normalized against K562 cells treated with 1% DMSO (n = 4).